Clinic
Garden State Infusions LLC
Garden State Infusions LLC was paid $346K by Medicaid between Mar 2021 and Jan 2024, across 12 billing codes. Its largest line is 87635, Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe — 53% of everything it billed.
33Billing provider infoGARDEN STATE INFUSIONS LLC
WEST NEW YORK, NJ 07093
WEST NEW YORK, NJ 07093
33aNPI1689264145assigned 01/19/2021
33bProvider typeClinic/Center
28Total paid$346K
24GClaims28,412
24DCodes billed12
24AFirst – last monthMar 2021 – Jan 2024
Compared with peers
Next to other Clinic/Center providers in New Jersey
Rank by total paid#46 of 97
Median peer was paid$318K
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 4,990 | $81K | |
| 2022 | 19,264 | $222K | |
| 2023 | 4,099 | $43K | |
| 2024incomplete | 59 | $100.72 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 53% | 7,881 | 5,186 | $183K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 24% | 7,413 | 4,751 | $83K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 9.6% | 714 | 600 | $33K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 8.4% | 3,271 | 2,199 | $29K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.5% | 4,573 | 3,067 | $9K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.8% | 3,009 | 2,691 | $6K |
| 86769 | <1% | 776 | 684 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 96 | 87 | $325.00 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 66 | 56 | $90.46 |
| 36415 | Collection of venous blood by venipuncture | <1% | 566 | 531 | $7.20 |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 0% | 20 | 18 | $0.00 |
| 86413 | 0% | 27 | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSANFILIPPO, LAUTARO (DIRECTOR)